First Time Loading...

Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 10.43 USD 4.4% Market Closed
Updated: May 2, 2024

Amicus Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amicus Therapeutics Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Amicus Therapeutics Inc
NASDAQ:FOLD
Cash from Financing Activities
$61.7m
CAGR 3-Years
-38%
CAGR 5-Years
-33%
CAGR 10-Years
8%
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$17.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$5.1B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
$21B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
23%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$562.2m
CAGR 3-Years
-4%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.8B
CAGR 3-Years
3%
CAGR 5-Years
-88%
CAGR 10-Years
N/A

See Also

What is Amicus Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
61.7m USD

Based on the financial report for Dec 31, 2023, Amicus Therapeutics Inc's Cash from Financing Activities amounts to 61.7m USD.

What is Amicus Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
8%

The average annual Cash from Financing Activities growth rates for Amicus Therapeutics Inc have been -38% over the past three years , -33% over the past five years , and 8% over the past ten years .